ETFOptimize | High-performance ETF-based Investment Strategies

Quantitative strategies, Wall Street-caliber research, and insightful market analysis since 1998.


ETFOptimize | HOME
Close Window

Science 37 Appoints Tyler Van Horn as CEO to Lead Next Era of Patient-Access Innovation

MORRISVILLE, N.C., Jan. 14, 2025 (GLOBE NEWSWIRE) -- Science 37, a leader in enhancing patient access to clinical trials, announces the appointment of Tyler Van Horn as Chief Executive Officer. Formerly the company’s Chief Commercial Officer, Van Horn’s appointment follows his pivotal role in driving operational excellence and shaping the company’s strategic direction to better prioritize client success – initiatives credited with driving growth for the company.

Since joining Science 37 in 2021, Van Horn has been a chief architect in assembling and empowering a team capable of matching or surpassing the testing standards and data quality of traditional clinical trial sites. By emphasizing the well-being and safety of patients through the delivery of convenient, at-home services, Van Horn sees Science 37 solving the most acute patient enrollment and study conduct pain points facing its clinical research clients.

“The future of clinical research lies in enabling therapies to reach their endpoints faster, gaining approval, and ensuring equitable, improved health outcomes for all,” said Van Horn. “As CEO, I am dedicated to supporting sponsors with our world-class research teams and innovative solutions. Our commitment to expanding patient access remains at the heart of everything we do, especially as we strive to reach underserved populations and drive meaningful change in healthcare.”

Van Horn’s elevation to CEO positions Science 37 to seamlessly build upon the learning of past successes. It also redoubles the company’s commitment to growth through purposeful innovation and enhanced solution delivery. By prioritizing the patient and study sponsors, Science 37 is leading the way, ushering in a new era of accessibility, diversity, and patient safety in clinical research.

For more information about Science 37 and its unique approach to clinical research, visit www.science37.com.

About Science 37

Science 37 accelerates clinical research by expanding patient access to trials, leading to faster approvals and better health outcomes. Our Metasite™ and Patient Recruitment solutions enable life sciences companies to reach beyond traditional means of conducting clinical research. To learn more, visit www.science37.com, or email science37@science37.com.

To view studies that Science 37 is actively recruiting for, please visit https://studies.science37.com/current-studies.

Media Inquiries

Science 37
pr@science37.com


Primary Logo

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.


 

IntelligentValue Home
Close Window

DISCLAIMER

All content herein is issued solely for informational purposes and is not to be construed as an offer to sell or the solicitation of an offer to buy, nor should it be interpreted as a recommendation to buy, hold or sell (short or otherwise) any security.  All opinions, analyses, and information included herein are based on sources believed to be reliable, but no representation or warranty of any kind, expressed or implied, is made including but not limited to any representation or warranty concerning accuracy, completeness, correctness, timeliness or appropriateness. We undertake no obligation to update such opinions, analysis or information. You should independently verify all information contained on this website. Some information is based on analysis of past performance or hypothetical performance results, which have inherent limitations. We make no representation that any particular equity or strategy will or is likely to achieve profits or losses similar to those shown. Shareholders, employees, writers, contractors, and affiliates associated with ETFOptimize.com may have ownership positions in the securities that are mentioned. If you are not sure if ETFs, algorithmic investing, or a particular investment is right for you, you are urged to consult with a Registered Investment Advisor (RIA). Neither this website nor anyone associated with producing its content are Registered Investment Advisors, and no attempt is made herein to substitute for personalized, professional investment advice. Neither ETFOptimize.com, Global Alpha Investments, Inc., nor its employees, service providers, associates, or affiliates are responsible for any investment losses you may incur as a result of using the information provided herein. Remember that past investment returns may not be indicative of future returns.

Copyright © 1998-2017 ETFOptimize.com, a publication of Optimized Investments, Inc. All rights reserved.